Big Pharma Fights ‘Tooth and Nail’ Against California Drug Vote
- Proposition 61 is state’s most expensive ballot fight of 2016
- Polls find voters supporting price limits for state agencies
This article is for subscribers only.
Drugmakers are becoming increasingly vocal in fighting a California ballot proposition on drug prices, concerned that the more $100 million in funding raised by lobbies opposing the initiative won’t be enough to stop it.
“We’re fighting that tooth and nail,” said John Lechleiter, chief executive officer of Eli Lilly & Co., said Tuesday on the company’s quarterly financial call.